Results 211 to 220 of about 103,286 (313)

Impact of a low‐carbohydrate diet on cardiometabolic parameters in individuals with and without diabetes: An 8‐year longitudinal study within the ELSA‐Brasil cohort

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Low‐carbohydrate diets (LCDs) are widely adopted for metabolic management, but their long‐term cardiometabolic effects in diverse populations remain unclear. We aimed to evaluate the association between self‐selected moderate LCD adherence and cardiometabolic parameters in individuals with and without diabetes.
Leticia Batista de Azevedo   +3 more
wiley   +1 more source

Editorial: Immunity, atherosclerosis, and cardiovascular disease: an interdisciplinary approach to cardiometabolic health. [PDF]

open access: yesFront Cardiovasc Med
Chelvanambi S   +5 more
europepmc   +1 more source

Identifying DASH Adherence Patterns and Their Association With Dietary Behaviors Among Adults With Hypertension

open access: yesResearch in Nursing &Health, EarlyView.
ABSTRACT The Dietary Approaches to Stop Hypertension (DASH) diet is effective in lowering blood pressure yet adherence to DASH remains low. Intuitive eating, a behavior that emphasizes responsiveness to hunger and satiety cues, may influence DASH adherence but has not been well studied among adults with hypertension.
Youran Lee   +7 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

open access: yesObesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo   +4 more
wiley   +1 more source

Childhood allostatic load predicts cardiometabolic health in adulthood. [PDF]

open access: yesProc Natl Acad Sci U S A
Hinz E   +4 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

open access: yesObesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone   +3 more
wiley   +1 more source

Time-Restricted Eating, Cardiometabolic Health in Obesity and The Optimal Length of the Eating Window. [PDF]

open access: yesCurr Nutr Rep
Silva BM   +9 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

open access: yesObesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy